Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels
MCT1 mRNA and protein expression distinguish MM cells derived from patients with elevated serum LDH levels from those without elevated serum LDH levels. However, only dual inhibition of MCT1 and MCT4 can disrupt lactate transport in multiple myeloma (MM) cells, with preferential cytotoxicity in MM cells from patients with high serum LDH levels.
Authors
- Matthew Smith
- Rafaël Fonseca (ORCID: https://orcid.org/0000-0002-5938-3769)
- Taro Hitosugi (ORCID: https://orcid.org/0000-0002-2898-6831)
- Dragan Jevremović (ORCID: https://orcid.org/0000-0002-1792-5822)
- Jadee Neff
- Sinto Sebastian
- Shaji Kunnathu Kumar (ORCID: https://orcid.org/0000-0001-5392-9284)
- Yogesh Chawla (ORCID: https://orcid.org/0000-0002-6679-518X)
- Laura A. Evans (ORCID: https://orcid.org/0000-0002-3011-4039)
- Jin Sung Jang (ORCID: https://orcid.org/0000-0001-7199-4418)
- Xuan-Mai Petterson
- Wilson I. Gonsalves (ORCID: https://orcid.org/0000-0001-6890-969X)
- Sonia Jain (ORCID: https://orcid.org/0000-0002-3728-6642)
- I. Rosario
- Emilie I. Anderson
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Duke University Health System (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cancer & Metabolism
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1186/s40170-025-00379-1
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- National Cancer Institute
- National Center for Advancing Translational Sciences